From: Discrete-choice modelling of patient preferences for modes of drug administration
MNL model | HMNL model | EMNL model | MMNL model | LCMNL model | |
---|---|---|---|---|---|
Variables: | \( \widehat{\mathrm{MWTP}}\left(95\%CI\right) \) | \( \widehat{\mathrm{MWTP}} \)(95% CI) | \( \widehat{\mathrm{MWTP}}\left(95\%CI\right) \) | \( \widehat{\mathrm{MWTP}}\left(95\%CI\right) \) | \( \widehat{\mathrm{MWTP}}\left(95\%CI\right) \) |
INTRAVENOUS | −2.12 (−4.09, −0.16)* | 1.17 (−0.74, 3.08) | 3.43 (1.73, 5.14)* | 2.31 (−2.86, 7.49)* | 5.85 (−50.38, 62.07) |
SUBCUTANEOUS | 2.35 (1.37, 3.32)* | 2.60 (1.58, 3.63)* | 0.23 (−0.52, 1.03) | −8.33 (−10.31, −6.34)* | 2.42 (−7.76, 12.59) |
INTRAMUSCULAR | −17.43 (−18.65, −16.22)* | −19.19 (−20.41, −17.97)* | −26.08 (−27.15, −25.01)* | −9.39 (−11, −7.77)* | −40.63 (−72.47, −8.80)* |
DOSFREQ | −0.08 (−0.09, −0.08)* | −0.09 (−0.094, −0.085)* | −0.12 (−0.13, −0.12)* | −0.10 (−0.10, −0.09)* | −0.23 (−0.30, −0.17)* |
NONCLINICAL_SELF | 21.45 (20.51, 22.39)* | 22.41 (21.48, 23.35)* | 26.35 (25.55, 27.16)* | 31.01 (29.87, 32.14)* | 28.57 (21.40, 35.74)* |
NONCLINICAL_SUPV | −15.45 (−16.06, −14.83)* | −15.74 (−16.36, −15.11)* | −15.46 (−15.95, −14.96)* | −19.83 (−20.64, −19.02)* | −15.53 (−26.04, −5.03)* |
DDA_MODERATE1 | 50.09 (48.91, 51.27)* | 49.40 (48.15, 50.65)* | 50.14 (49.02, 51.27)* | 58.88 (57.65, 60.11)* | 84.71 (67.59, 101.82)* |
DDA_MODERATE2 | −34 (−35.15, −32.85)* | −35.24 (−36.51, −33.97)* | −38.86 (−39.89, −37.83)* | −43.13 (−44.35, −41.92)* | −58.84 (−72.28, −45.40)* |
DDA_SEVERE | −66.36 (−67.74, −64.99)* | −68.64 (−70.14, −67.14)* | −71.55 (−72.80, −70.30)* | −73.64 (−75.15, −72.14)* | −94.50 (−117.91, −71.10)* |
RAE_MODERATE | 22.06 (21.20, 22.92)* | 22.64 (21.74, 23.53)* | 26.37 (25.59, 27.14)* | 30.32 (29.23, 31.41)* | 23.49 (17.29, 29.70)* |
RAE_SEVERE | −94.65 (−96.64, −92.65)* | −94.77 (−96.85, −92.70)* | −94.75 (−96.58, −92.93)* | −116.08 (−117.65, −114.51)* | −130.32 (−165.12, −95.53)* |